Tokyo, Dec. 16 (Jiji Press)–Takeda Pharmaceutical Co. <4502> said Thursday that it has applied to the Japanese health ministry for approval to manufacture and sell U.S. biopharmaceutical firm Novavax Inc.’s coronavirus vaccine in Japan.
If the vaccine gains approval, Takeda aims to start supplying the product early next year. The data submitted by the Japanese firm include those for booster shots.
The recombinant protein vaccine was shown to be about 90 pct effective against the virus in clinical trials.
Takeda will manufacture 250 million doses of the vaccine per year at a factory in Yamaguchi Prefecture, western Japan, on behalf of Novavax. Of them, 150 million doses will be supplied to the Japanese government next year.